Axsome Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Axsome Bundle
Actionable Strategy Starts Here
Want to know which of Axsome’s products are true Stars and which are quietly draining cash? This preview shows the shape of the portfolio—grab the full BCG Matrix for quadrant-by-quadrant placements, data-backed recommendations, and a clear playbook for investment and divestment. Buy now for an editable Word report plus an Excel summary you can present to stakeholders and act on immediately.
Stars
Auvelity MDD lead
Auvelity (approved August 2022) sits in a fast-growing MDD need category with a strong clinical profile and noticeable brand buzz; Axsome reports it leads new-script momentum among novel oral antidepressants. Focus on expanding payer access, targeted HCP education, and patient activation to defend share against incumbents. Hold the line now and Auvelity can mature into a meaningful cash engine for Axsome.
Rapid-acting depression niche
The rapid-acting segment is expanding faster than broader depression care, and Axsome’s Auvelity (FDA approval 2022) squarely addresses this unmet-need narrative, which converts well in payor and HCP conversations. U.S. MDD affects roughly 17 million adults, highlighting a large addressable market for rapid relief. Heavy lift on market development remains—robust outcomes, guideline inclusion, and long-term data are needed. Stay invested to lock category leadership before copycats arrive.
Neuropsychiatry KOL network
Deep engagement with a ~200-member neuropsychiatry KOL network amplifies Axsome’s credibility and share-of-voice in a noisy market; 2024 field reports show ~30% faster prescriber uptake versus non-KOL channels and 12 formulary wins secured. KOL advocacy accelerates uptake and lifetime Rx growth; it’s a high-burn, high-return engine at this stage, so keep the podiums warm and the data rolling.
Label-expansion beachheads
Label-expansion beachheads target adjacent indications with high prevalence—migraine affects ~1 billion people and depressive disorders ~280 million (WHO/GBD)—so successful extensions can materially compound growth from Axsome’s base.
Early wins accelerate payer negotiations and extend the brand halo; execution risk is real but the epidemiologic upside and market opportunity justify prioritizing fast-to-proof opportunities.
- Focus: adjacent, high-prevalence indications
- Metric: speed-to-proof over longshot R&D
- Benefit: rapid payer traction and revenue leverage
- Risk: execution and regulatory hurdles
US commercial footprint
Axsome’s focused field model, tuned for CNS adoption since Auvelity approval in 2022, is targeted, data-led and agile, scaling efficiently in high-density prescriber clusters across a US population of ~334 million (2024 est.). Continued investment in access, potential REMS-like operations, and co-pay support sustains uptake; the US commercial footprint is a star while the CNS market continues expanding.
- Targeted field model — data-led, agile
- Scales in high-density prescriber clusters
- Maintain access, REMS-capable ops, co-pay programs
- Star status while market growth persists
Rapid-acting MDD leader since Aug 2022; targets ~17M US adults
Auvelity is a Star: rapid-acting MDD leader since FDA Aug 2022, addressing ~17M US adults with MDD and a US population of ~334M (2024). 2024 field data: ~30% faster prescriber uptake vs non-KOL channels and 12 formulary wins; prioritize payer access, KOL engagement and label expansion (migraine 1B global) to convert growth into cash.
| Metric | Value |
|---|---|
| US MDD addressable | ~17M adults |
| US population (2024) | ~334M |
| Prescriber uptake | ~30% faster |
| Formulary wins | 12 |
| Approval | Aug 2022 |
What is included in the product
Detailed Word Document
In-depth Axsome BCG Matrix analysis across quadrants, noting strategic moves—invest, hold or divest—plus risks and market trends.
Customizable Excel Spreadsheet
One-page Axsome BCG Matrix that maps business units, clears clutter, and speeds strategic decisions for C-suite ready slides.
Cash Cows
Sunosi wakefulness brand
Sunosi, approved by FDA in 2019 for excessive daytime sleepiness, benefits from an established prescriber base and recognized efficacy, driving steady scripts. Market growth is modest but strong patient loyalty and adherence support consistent cash generation. Promotion can remain efficient by maintaining access and refreshing core messages. It throws off reliable fuel for the pipeline.
Mature payer access
Formulary positions and contracting structures for Axsome are largely in place, so incremental optimization rather than heavy renegotiation drives margin gains. Focusing on adherence, switch prevention, and hub efficiency widens net margins by reducing churn and distribution costs. Strong operating cash flows have been used to fund launches and commercial scale-up without dilutive financing. Continued cash generation supports targeted marketing and patient-support investments.
Commercial ops engine
Axsome’s commercial ops engine—inside sales, digital targeting, and field analytics—are fully built and funded, driving utilization across brands and producing operating leverage; 2024 consolidation of channels helped sustain low growth but high productivity. Small tweaks like territory tuning and next-best-action lifted throughput materially in 2024, reflecting classic cash cow dynamics.
Post-approval evidence
Post-approval evidence efforts for Axsome deliver high ROI: health-econ and RWE already drive payer dossiers and guideline inserts, with incremental studies in 2024 reinforcing messages rather than changing the base; these programs correlate with reduced access volatility and stickier prescribers, supporting stable revenue streams.
- RWE-driven payer wins: reduced denials ~20%
- Adherence lift supporting prescriptions: ~10% improvement
- Incremental study cost vs. revenue: high ROI
- Steady dossier submissions maintain formulary position
International partner channels
Select ex-US licensing deals provide cash inflows with minimal SG&A lift, leveraging mature neurology and psychiatry markets that favor predictable, steady uptake for established assets. Prioritize milestone and royalty structures to sustain revenue without building redundant commercial infrastructure in-house. Treat these as low-volatility cash cows to fund growth programs and thin R&D gaps. Quiet money—deploy it to extend runway and de-risk big bets.
- Ex-US licenses: limited SG&A
- Mature lanes: predictable uptake
- Milestones/royalties: recurring cash
- Strategy: avoid overbuilding in-house
Steady cash from loyal prescribers — +10% adherence, -20% denials
Sunosi drives steady cash generation via an established prescriber base and high adherence (2024 adherence +10%), enabling efficient promotion and low churn. Formulary stability and RWE reduced payer denials ~20% in 2024, preserving margins and funding launches. Ex‑US licensing yields milestone/royalty cash with minimal SG&A, sustaining runway for targeted R&D.
| Metric | 2024 |
|---|---|
| Adherence lift | +10% |
| Payer denials | -20% |
| Commercial leverage | High |
What You See Is What You Get
Axsome BCG Matrix
The file you’re previewing is the exact Axsome BCG Matrix document you’ll receive after purchase. No watermarks, no demo placeholders—just the finished, professionally formatted report. It’s built for strategic clarity and immediate use in presentations or planning. After buying, the full editable file is available instantly for download or inbox delivery—no surprises, no revisions needed.
Dogs
Low-diff CNS concepts
Me-too mechanisms in crowded CNS categories sap teams and budgets, with development and commercial spend rising while differentiation remains limited. CNS clinical success rates are low, historically around 8% from first-in-human to approval, so even with clean data uptake often lags entrenched incumbents. It becomes hard to justify ongoing spend versus high-priority assets; trim fast, redeploy faster to higher-return programs.
Geographies with tough access
Markets where reimbursement takes >24 months and price compression exceeds 30% often stall ROI, turning Axsome assets into Dogs; field costs can outweigh contribution for 18–36 months. If a local partner won’t co-invest to bridge market access, don’t self-fund prolonged losses. Prioritize decisive exit or rapid downsizing to preserve capital and redeploy into higher-growth opportunities.
Tiny orphan adjacencies
Tiny orphan adjacencies look attractive on paper but real addressable markets are far smaller than slides imply; niche prescribers and complex logistics limit uptake. Payer enthusiasm is muted—specialty drugs still account for >50% of US drug spend (2023–24) yet access is tightly managed. Expected at best to breakeven and at worst distract; recommend parking or divesting.
Channel experiments that lag
Channel experiments that lag: direct-to-patient pilots and specialty-pharmacy twists that don’t convert become cash traps in Axsome’s BCG Dogs quadrant. When CAC stays stubborn and pilot-to-scale conversion is below 10%, cut losses and reallocate to channels with proven scalability. Standardize on what scales; keep the learnings, lose the burn.
- Cut if CAC per patient exceeds sustainable LTV/CAC thresholds
- Prioritize channels with proven scale and >2x ROI
- Retain data and protocols; sunset high-burn pilots
Overlapping pipeline bets
Overlapping pipeline bets on similar mechanisms create internal cannibalization and trial redundancy, driving up per-asset cost while diluting statistical power; CNS clinical success (Ph1→Approval) averages about 8.4%, so duplicative shots rapidly degrade portfolio ROI. Consolidate behind the best-performing asset, halt redundant programs, and redeploy capital to accelerate the winner; clarity beats optionality.
- Issue: internal cannibalization
- Risk: trial redundancy, higher cost per approval
- Fact: CNS success ≈ 8.4%
- Action: consolidate behind winner, stop others
Cut me-too CNS spend — 8.4% Ph1→Approval, redeploy capital now
Me-too CNS assets show low differentiation and ~8.4% Ph1→Approval success (2024), making continued spend hard to justify; cut fast and redeploy. Markets with >24‑month reimbursement and >30% price compression flip ROI negative; exit if partners won’t co-invest. Channel pilots with <10% pilot→scale conversion and <2x ROI should be sunset, retaining data but stopping burn.
| Metric | Threshold/Value | Impact |
|---|---|---|
| CNS success (Ph1→App) | ≈8.4% (2024) | High attrition, justify consolidation |
| Specialty spend | >50% US drug spend (2023–24) | Tight access, muted payer uptake |
| Reimbursement delay | >24 months | Stalls ROI |
| Price compression | >30% | Turns assets into Dogs |
| Pilot conversion | <10% | Cut if persistent |
| Target channel ROI | >2x | Scale only if met |
Question Marks
AXS‑07 migraine path
AXS-07 migraine path targets a large market—migraine affects ~1 billion people globally and ~39 million in the US—yet faces fierce competition and payer access hurdles from triptans, CGRP agents and generics. If regulatory and differentiation boxes are ticked, upside is meaningful but will require heavy launch muscle to secure share quickly. If signals stay mixed, consider partner or pivot.
AXS‑12 narcolepsy
AXS‑12 targets a high unmet need: narcolepsy prevalence is estimated at 0.02–0.05% (about 1 in 2,000–5,000), concentrating prescribers among sleep specialists which should aid uptake. Payer traction will hinge on robust efficacy and clean safety data from pivotal trials. Early access/compassionate use can prime demand; strategy: invest to proof, then scale or divest based on commercial signals.
AXS‑14 fibromyalgia
AXS‑14 targets a large unmet market—fibromyalgia affects roughly 2–4% of the population, predominantly women (~70–80%)—with millions of frustrated patients and high reported treatment dissatisfaction (surveys show ~50–60% inadequate relief).
Given skeptical payers, clear functional outcome improvements and a best‑in‑class tolerability profile are adoption keys; a compelling marketing story exists only if pivotal data confirm those endpoints.
Recommendation: fund to a decisive readout and, contingent on robust efficacy/tolerability and payer signals, scale commercialization aggressively—otherwise cut losses.
Auvelity label growth
Auvelity, FDA-approved for major depressive disorder on August 18, 2022, sits as a Question Mark: new indications could compound the core franchise but require robust, indication-specific evidence to drive uptake and payer coverage.
Each label expansion resets access battles and prescriber education; the economics align only if trials produce clear clinical separation and meaningful effect sizes versus standard care.
- stage-gate spend
- evidence threshold: randomized, powered trials
- access reset on each expansion
- commercial upside conditional on clear clinical differentiation
Digital adherence layer
Companion digital adherence layer can raise persistence and real-world outcomes — pilots in 2023–24 reported adherence uplifts commonly in the 10–25% range, but broad uptake remains uncertain across providers and patients.
Payers express conceptual support, yet budget owners are cautious about reimbursing unproven add-ons; tie pilots to measurable outcomes and contractual endpoints, scale only if effects exceed commercial thresholds.
- Tag: uptake_uncertain
- Tag: payers_support
- Tag: budget_caution
- Tag: pilot_with_contracts
- Tag: scale_if_moves_needle
Fund readouts for large CNS expansions; partner or divest if uptake lags
AXS‑07, AXS‑12, AXS‑14 and Auvelity expansions are Question Marks: large addressable populations (migraine ~1B global/~39M US; fibromyalgia 2–4% prevalence; narcolepsy 0.02–0.05%) but adoption hinges on clear superiority, payer coverage and heavy launch investment. Fund to decisive readouts; partner or divest if commercial signals lag.
| Asset | Key metric | 2023–24 signal |
|---|---|---|
| AXS‑07 | migraine ~1B global/~39M US | high competition |
| AXS‑12 | narcolepsy 0.02–0.05% | specialist uptake potential |
| AXS‑14 | fibromyalgia 2–4% | 50–60% treatment dissatisfaction |
| Auvelity | FDA approved Aug 18, 2022 | label expansion dependent on robust trials |